Detalles de la búsqueda
1.
Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism.
Drug Metab Dispos
; 49(7): 548-562, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33952610
2.
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Br J Clin Pharmacol
; 86(2): 338-351, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31658377
3.
Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
Pulm Pharmacol Ther
; 57: 101809, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31195091
4.
CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
Biopharm Drug Dispos
; 39(8): 394-402, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171694
5.
Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
Drug Metab Dispos
; 45(7): 817-825, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28442499
6.
Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjectsâ©.
Int J Clin Pharmacol Ther
; 55(2): 147-155, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27841152
7.
Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
Pulm Pharmacol Ther
; 37: 30-6, 2016 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26845343
8.
Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.
Pharm Res
; 32(5): 1764-78, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425054
9.
Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Int J Clin Pharmacol Ther
; 53(7): 550-6, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25943176
10.
Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Int J Clin Pharmacol Ther
; 53(5): 398-407, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25740265
11.
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
Eur J Drug Metab Pharmacokinet
; 40(2): 203-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24705947
12.
Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.
Drug Metab Dispos
; 41(9): 1626-41, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23775850
13.
Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma.
Anal Bioanal Chem
; 405(1): 215-23, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23064707
14.
A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants.
Clin Pharmacol Drug Dev
; 12(2): 122-131, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495282
15.
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Pharmaceutics
; 15(9)2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37765235
16.
Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations.
Int J Clin Pharmacol Ther
; 50(8): 545-56, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22735463
17.
Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(11): 1253-1263, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35962468
18.
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Eur J Pharm Sci
; 172: 106155, 2022 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247543
19.
Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.
J Clin Pharmacol
; 62(4): 520-531, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34738233
20.
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
Clin Transl Sci
; 15(1): 118-129, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34432364